Critical Thinking in Medicine (Dr. E. Farbman) - October 6, 2008
Drug Development Process
New New Oral Anticoagulants 2014
FDA Advisory Panel Linx Presentation 011112
Phase II/III Design: Case Study Case study: Seamless Phase II/III Design for Registration Program Jeff Maca, Ph.D. Senior Associate Director Novartis Pharmaceuticals.
Clinical Epidemiology Study Who benefits? How do we know? B Lynn Beattie MD FRCPC Professor Emeritus Div Geri Med, Dept Med, UBC Medical Director UBCH.
IDEs in a New Device Space: An FDA View of Mitral John Laschinger, MD CDRH, ODE, DCD, SHDB Predictable And SuStainable Implementation Of National Registries.
Portfolio Management and R & D Productivity Anirban Bhattacharya, PhD 8th Annual Project and Portfolio Management Forum.
Game plan for therapeutic cancer vaccines
Objectives Provide PAAB code advice in response to proposed campaign plans. Make rulings about whether specific activities and/or messages are aligned.
Squire, Sanders & Dempsey L.L.P. Roadmap to Emerging Regions: Clinical Trials in Developing Countries International Clinical Trials Conference.
Optimizing Treatment for Her 2 Positive Early Stage Breast Cancer Patients Sunil Verma MD, MSEd, FRCPC Medical Oncologist Chair, Breast Medical Oncology.
